Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch).

Trevi Therapeutics Selected to Present at the American Society of Nephrologys Kidney Week 2015 at High-Impact Clinical Trials Session with Phase 2/3 Data for Nalbuphine ER
Presentation Abstract: Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of Safety and Anti-Pruritic Efficacy of Nalbuphine HCI ER Tablets in Hemodialysis Patients with Uremic Pruritus
Trevi Therapeutics Announces Positive Results from Phase 2/3 Trial in Uremic Pruritus
Oral Nalbuphine ER trial achieved statistically significant results on the primary endpoint of reducing itch intensity and also demonstrated sustained duration of effect